nodes	percent_of_prediction	percent_of_DWPC	metapath
Toremifene—CYP1A2—Carmustine—lymphatic system cancer	0.233	0.334	CbGbCtD
Toremifene—ABCB1—Mitoxantrone—lymphatic system cancer	0.0959	0.137	CbGbCtD
Toremifene—CYP3A4—Cytarabine—lymphatic system cancer	0.0834	0.12	CbGbCtD
Toremifene—CYP3A4—Teniposide—lymphatic system cancer	0.0821	0.118	CbGbCtD
Toremifene—ABCB1—Vincristine—lymphatic system cancer	0.066	0.0946	CbGbCtD
Toremifene—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0574	0.0824	CbGbCtD
Toremifene—ABCB1—Methotrexate—lymphatic system cancer	0.0399	0.0573	CbGbCtD
Toremifene—CYP3A4—Vincristine—lymphatic system cancer	0.0395	0.0567	CbGbCtD
Toremifene—Thrombosis—Mechlorethamine—lymphatic system cancer	0.00874	0.0289	CcSEcCtD
Toremifene—Paresis—Vincristine—lymphatic system cancer	0.00671	0.0222	CcSEcCtD
Toremifene—Deep vein thrombosis—Fludarabine—lymphatic system cancer	0.00659	0.0218	CcSEcCtD
Toremifene—Thrombophlebitis—Mechlorethamine—lymphatic system cancer	0.00518	0.0171	CcSEcCtD
Toremifene—Thromboembolic event—Methotrexate—lymphatic system cancer	0.00441	0.0146	CcSEcCtD
Toremifene—Cyst—Carmustine—lymphatic system cancer	0.00384	0.0127	CcSEcCtD
Toremifene—Thrombosis—Carmustine—lymphatic system cancer	0.00362	0.012	CcSEcCtD
Toremifene—Jaundice—Mechlorethamine—lymphatic system cancer	0.00337	0.0111	CcSEcCtD
Toremifene—Paresis—Methotrexate—lymphatic system cancer	0.00326	0.0108	CcSEcCtD
Toremifene—Liver function test abnormal—Teniposide—lymphatic system cancer	0.00305	0.0101	CcSEcCtD
Toremifene—Cardiac failure—Fludarabine—lymphatic system cancer	0.00298	0.00985	CcSEcCtD
Toremifene—Alopecia—Mechlorethamine—lymphatic system cancer	0.00274	0.00907	CcSEcCtD
Toremifene—Liver function test abnormal—Fludarabine—lymphatic system cancer	0.00268	0.00887	CcSEcCtD
Toremifene—Coordination abnormal—Carmustine—lymphatic system cancer	0.00261	0.00863	CcSEcCtD
Toremifene—Pulmonary embolism—Carmustine—lymphatic system cancer	0.00256	0.00847	CcSEcCtD
Toremifene—Neuropathy peripheral—Teniposide—lymphatic system cancer	0.0025	0.00826	CcSEcCtD
Toremifene—Angina pectoris—Fludarabine—lymphatic system cancer	0.00245	0.00809	CcSEcCtD
Toremifene—Sweating—Teniposide—lymphatic system cancer	0.00244	0.00808	CcSEcCtD
Toremifene—Vertigo—Mechlorethamine—lymphatic system cancer	0.00243	0.00802	CcSEcCtD
Toremifene—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00242	0.00799	CcSEcCtD
Toremifene—Appetite absent—Methotrexate—lymphatic system cancer	0.00239	0.00789	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00229	0.00755	CcSEcCtD
Toremifene—Abnormal vision—Carmustine—lymphatic system cancer	0.00224	0.00739	CcSEcCtD
Toremifene—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.00221	0.0073	CcSEcCtD
Toremifene—Myocardial infarction—Fludarabine—lymphatic system cancer	0.0022	0.00726	CcSEcCtD
Toremifene—Neuropathy peripheral—Fludarabine—lymphatic system cancer	0.0022	0.00726	CcSEcCtD
Toremifene—Arthritis—Bleomycin—lymphatic system cancer	0.00219	0.00725	CcSEcCtD
Toremifene—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00216	0.00714	CcSEcCtD
Toremifene—Thrombophlebitis—Carmustine—lymphatic system cancer	0.00215	0.0071	CcSEcCtD
Toremifene—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00214	0.00708	CcSEcCtD
Toremifene—Anorexia—Mechlorethamine—lymphatic system cancer	0.0021	0.00695	CcSEcCtD
Toremifene—Chills—Teniposide—lymphatic system cancer	0.00205	0.00679	CcSEcCtD
Toremifene—Arrhythmia—Teniposide—lymphatic system cancer	0.00204	0.00676	CcSEcCtD
Toremifene—Alopecia—Teniposide—lymphatic system cancer	0.00202	0.00668	CcSEcCtD
Toremifene—Polyp—Methotrexate—lymphatic system cancer	0.00195	0.00645	CcSEcCtD
Toremifene—Vaginal discharge—Methotrexate—lymphatic system cancer	0.00195	0.00645	CcSEcCtD
Toremifene—Deep vein thrombosis—Methotrexate—lymphatic system cancer	0.00195	0.00645	CcSEcCtD
Toremifene—Visual impairment—Fludarabine—lymphatic system cancer	0.00194	0.00641	CcSEcCtD
Toremifene—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00192	0.00634	CcSEcCtD
Toremifene—Diplopia—Carmustine—lymphatic system cancer	0.00186	0.00615	CcSEcCtD
Toremifene—Embolism—Methotrexate—lymphatic system cancer	0.00185	0.00611	CcSEcCtD
Toremifene—Chills—Fludarabine—lymphatic system cancer	0.00181	0.00596	CcSEcCtD
Toremifene—Arrhythmia—Fludarabine—lymphatic system cancer	0.0018	0.00594	CcSEcCtD
Toremifene—Leukopenia—Teniposide—lymphatic system cancer	0.00178	0.00589	CcSEcCtD
Toremifene—Alopecia—Fludarabine—lymphatic system cancer	0.00178	0.00587	CcSEcCtD
Toremifene—Cyst—Methotrexate—lymphatic system cancer	0.00178	0.00587	CcSEcCtD
Toremifene—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.00177	0.00586	CcSEcCtD
Toremifene—Malnutrition—Fludarabine—lymphatic system cancer	0.00175	0.00579	CcSEcCtD
Toremifene—Ataxia—Carmustine—lymphatic system cancer	0.00175	0.00578	CcSEcCtD
Toremifene—Liver disorder—Methotrexate—lymphatic system cancer	0.00174	0.00576	CcSEcCtD
Toremifene—Liver function test abnormal—Carmustine—lymphatic system cancer	0.00172	0.00568	CcSEcCtD
Toremifene—Chest pain—Teniposide—lymphatic system cancer	0.0017	0.00561	CcSEcCtD
Toremifene—Ataxia—Vincristine—lymphatic system cancer	0.00167	0.00552	CcSEcCtD
Toremifene—Oedema—Teniposide—lymphatic system cancer	0.00163	0.00537	CcSEcCtD
Toremifene—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00162	0.00535	CcSEcCtD
Toremifene—Myocardial infarction—Bleomycin—lymphatic system cancer	0.00161	0.00532	CcSEcCtD
Toremifene—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00159	0.00526	CcSEcCtD
Toremifene—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00157	0.0052	CcSEcCtD
Toremifene—Leukopenia—Fludarabine—lymphatic system cancer	0.00157	0.00518	CcSEcCtD
Toremifene—Pruritus—Mechlorethamine—lymphatic system cancer	0.00156	0.00516	CcSEcCtD
Toremifene—Anorexia—Teniposide—lymphatic system cancer	0.00155	0.00512	CcSEcCtD
Toremifene—Dyspnoea—Teniposide—lymphatic system cancer	0.00145	0.00479	CcSEcCtD
Toremifene—Oedema—Fludarabine—lymphatic system cancer	0.00143	0.00472	CcSEcCtD
Toremifene—Decreased appetite—Teniposide—lymphatic system cancer	0.00141	0.00467	CcSEcCtD
Toremifene—Neuropathy peripheral—Carmustine—lymphatic system cancer	0.00141	0.00465	CcSEcCtD
Toremifene—Vomiting—Mechlorethamine—lymphatic system cancer	0.0014	0.00463	CcSEcCtD
Toremifene—Nervous system disorder—Fludarabine—lymphatic system cancer	0.0014	0.00463	CcSEcCtD
Toremifene—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.0014	0.00462	CcSEcCtD
Toremifene—Rash—Mechlorethamine—lymphatic system cancer	0.00139	0.0046	CcSEcCtD
Toremifene—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00139	0.00459	CcSEcCtD
Toremifene—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00138	0.00457	CcSEcCtD
Toremifene—Anorexia—Fludarabine—lymphatic system cancer	0.00136	0.0045	CcSEcCtD
Toremifene—Weight increased—Mitoxantrone—lymphatic system cancer	0.00136	0.0045	CcSEcCtD
Toremifene—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00135	0.00446	CcSEcCtD
Toremifene—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00134	0.00443	CcSEcCtD
Toremifene—Myocardial infarction—Vincristine—lymphatic system cancer	0.00134	0.00443	CcSEcCtD
Toremifene—Musculoskeletal stiffness—Methotrexate—lymphatic system cancer	0.00132	0.00437	CcSEcCtD
Toremifene—Chills—Bleomycin—lymphatic system cancer	0.00132	0.00437	CcSEcCtD
Toremifene—Skin discolouration—Methotrexate—lymphatic system cancer	0.00131	0.00434	CcSEcCtD
Toremifene—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00131	0.00434	CcSEcCtD
Toremifene—Sweating—Vincristine—lymphatic system cancer	0.00131	0.00434	CcSEcCtD
Toremifene—Nausea—Mechlorethamine—lymphatic system cancer	0.00131	0.00433	CcSEcCtD
Toremifene—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00131	0.00432	CcSEcCtD
Toremifene—Alopecia—Bleomycin—lymphatic system cancer	0.0013	0.00431	CcSEcCtD
Toremifene—Jaundice—Mitoxantrone—lymphatic system cancer	0.0013	0.00429	CcSEcCtD
Toremifene—Sweating—Mitoxantrone—lymphatic system cancer	0.00128	0.00422	CcSEcCtD
Toremifene—Dyspnoea—Fludarabine—lymphatic system cancer	0.00127	0.00421	CcSEcCtD
Toremifene—Decreased appetite—Fludarabine—lymphatic system cancer	0.00124	0.00411	CcSEcCtD
Toremifene—Visual impairment—Carmustine—lymphatic system cancer	0.00124	0.0041	CcSEcCtD
Toremifene—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00123	0.00408	CcSEcCtD
Toremifene—Fatigue—Fludarabine—lymphatic system cancer	0.00123	0.00407	CcSEcCtD
Toremifene—Pain—Fludarabine—lymphatic system cancer	0.00122	0.00404	CcSEcCtD
Toremifene—Constipation—Fludarabine—lymphatic system cancer	0.00122	0.00404	CcSEcCtD
Toremifene—Eye disorder—Carmustine—lymphatic system cancer	0.0012	0.00398	CcSEcCtD
Toremifene—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.00119	0.00392	CcSEcCtD
Toremifene—Asthenia—Teniposide—lymphatic system cancer	0.00117	0.00386	CcSEcCtD
Toremifene—Pruritus—Teniposide—lymphatic system cancer	0.00115	0.0038	CcSEcCtD
Toremifene—Arrhythmia—Carmustine—lymphatic system cancer	0.00115	0.0038	CcSEcCtD
Toremifene—Leukopenia—Bleomycin—lymphatic system cancer	0.00115	0.0038	CcSEcCtD
Toremifene—Alopecia—Carmustine—lymphatic system cancer	0.00114	0.00376	CcSEcCtD
Toremifene—Mental disorder—Carmustine—lymphatic system cancer	0.00113	0.00373	CcSEcCtD
Toremifene—Malnutrition—Carmustine—lymphatic system cancer	0.00112	0.0037	CcSEcCtD
Toremifene—Angiopathy—Vincristine—lymphatic system cancer	0.00112	0.00368	CcSEcCtD
Toremifene—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00111	0.00366	CcSEcCtD
Toremifene—Chest pain—Bleomycin—lymphatic system cancer	0.00109	0.00361	CcSEcCtD
Toremifene—Alopecia—Vincristine—lymphatic system cancer	0.00109	0.00359	CcSEcCtD
Toremifene—Back pain—Carmustine—lymphatic system cancer	0.00108	0.00358	CcSEcCtD
Toremifene—Mental disorder—Vincristine—lymphatic system cancer	0.00108	0.00356	CcSEcCtD
Toremifene—Chills—Mitoxantrone—lymphatic system cancer	0.00107	0.00355	CcSEcCtD
Toremifene—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00107	0.00353	CcSEcCtD
Toremifene—Alopecia—Mitoxantrone—lymphatic system cancer	0.00106	0.0035	CcSEcCtD
Toremifene—Vision blurred—Carmustine—lymphatic system cancer	0.00106	0.00349	CcSEcCtD
Toremifene—Tremor—Carmustine—lymphatic system cancer	0.00105	0.00347	CcSEcCtD
Toremifene—Oedema—Bleomycin—lymphatic system cancer	0.00105	0.00346	CcSEcCtD
Toremifene—Back pain—Vincristine—lymphatic system cancer	0.00103	0.00342	CcSEcCtD
Toremifene—Vomiting—Teniposide—lymphatic system cancer	0.00103	0.00342	CcSEcCtD
Toremifene—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00103	0.00339	CcSEcCtD
Toremifene—Asthenia—Fludarabine—lymphatic system cancer	0.00103	0.00339	CcSEcCtD
Toremifene—Rash—Teniposide—lymphatic system cancer	0.00103	0.00339	CcSEcCtD
Toremifene—Dermatitis—Teniposide—lymphatic system cancer	0.00102	0.00339	CcSEcCtD
Toremifene—Headache—Teniposide—lymphatic system cancer	0.00102	0.00337	CcSEcCtD
Toremifene—Pruritus—Fludarabine—lymphatic system cancer	0.00101	0.00334	CcSEcCtD
Toremifene—Back pain—Mitoxantrone—lymphatic system cancer	0.00101	0.00333	CcSEcCtD
Toremifene—Leukopenia—Carmustine—lymphatic system cancer	0.001	0.00332	CcSEcCtD
Toremifene—Anorexia—Bleomycin—lymphatic system cancer	0.000999	0.0033	CcSEcCtD
Toremifene—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000996	0.00329	CcSEcCtD
Toremifene—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000982	0.00324	CcSEcCtD
Toremifene—Nausea—Teniposide—lymphatic system cancer	0.000966	0.00319	CcSEcCtD
Toremifene—Vertigo—Vincristine—lymphatic system cancer	0.000961	0.00318	CcSEcCtD
Toremifene—Leukopenia—Vincristine—lymphatic system cancer	0.000958	0.00316	CcSEcCtD
Toremifene—Chest pain—Carmustine—lymphatic system cancer	0.000954	0.00315	CcSEcCtD
Toremifene—Dyspnoea—Bleomycin—lymphatic system cancer	0.000934	0.00309	CcSEcCtD
Toremifene—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000933	0.00308	CcSEcCtD
Toremifene—Oedema—Carmustine—lymphatic system cancer	0.000915	0.00302	CcSEcCtD
Toremifene—Decreased appetite—Bleomycin—lymphatic system cancer	0.000911	0.00301	CcSEcCtD
Toremifene—Vomiting—Fludarabine—lymphatic system cancer	0.000909	0.003	CcSEcCtD
Toremifene—Rash—Fludarabine—lymphatic system cancer	0.000901	0.00298	CcSEcCtD
Toremifene—Dermatitis—Fludarabine—lymphatic system cancer	0.0009	0.00298	CcSEcCtD
Toremifene—Pain—Bleomycin—lymphatic system cancer	0.000896	0.00296	CcSEcCtD
Toremifene—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000896	0.00296	CcSEcCtD
Toremifene—Headache—Fludarabine—lymphatic system cancer	0.000895	0.00296	CcSEcCtD
Toremifene—Chest pain—Mitoxantrone—lymphatic system cancer	0.000887	0.00293	CcSEcCtD
Toremifene—Lethargy—Methotrexate—lymphatic system cancer	0.00088	0.00291	CcSEcCtD
Toremifene—Oedema—Vincristine—lymphatic system cancer	0.000873	0.00289	CcSEcCtD
Toremifene—Anorexia—Carmustine—lymphatic system cancer	0.000872	0.00288	CcSEcCtD
Toremifene—Nervous system disorder—Vincristine—lymphatic system cancer	0.000856	0.00283	CcSEcCtD
Toremifene—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000855	0.00283	CcSEcCtD
Toremifene—Oedema—Mitoxantrone—lymphatic system cancer	0.00085	0.00281	CcSEcCtD
Toremifene—Nausea—Fludarabine—lymphatic system cancer	0.000849	0.00281	CcSEcCtD
Toremifene—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000844	0.00279	CcSEcCtD
Toremifene—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000833	0.00275	CcSEcCtD
Toremifene—Anorexia—Vincristine—lymphatic system cancer	0.000832	0.00275	CcSEcCtD
Toremifene—Insomnia—Carmustine—lymphatic system cancer	0.000827	0.00273	CcSEcCtD
Toremifene—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000826	0.00273	CcSEcCtD
Toremifene—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000822	0.00272	CcSEcCtD
Toremifene—Mood swings—Methotrexate—lymphatic system cancer	0.000817	0.0027	CcSEcCtD
Toremifene—Dyspnoea—Carmustine—lymphatic system cancer	0.000816	0.00269	CcSEcCtD
Toremifene—Anorexia—Mitoxantrone—lymphatic system cancer	0.000811	0.00268	CcSEcCtD
Toremifene—Ataxia—Methotrexate—lymphatic system cancer	0.000811	0.00268	CcSEcCtD
Toremifene—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000796	0.00263	CcSEcCtD
Toremifene—Decreased appetite—Carmustine—lymphatic system cancer	0.000795	0.00263	CcSEcCtD
Toremifene—Insomnia—Vincristine—lymphatic system cancer	0.00079	0.00261	CcSEcCtD
Toremifene—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00079	0.00261	CcSEcCtD
Toremifene—Pain—Carmustine—lymphatic system cancer	0.000782	0.00258	CcSEcCtD
Toremifene—Constipation—Carmustine—lymphatic system cancer	0.000782	0.00258	CcSEcCtD
Toremifene—Breast disorder—Methotrexate—lymphatic system cancer	0.000779	0.00257	CcSEcCtD
Toremifene—Decreased appetite—Vincristine—lymphatic system cancer	0.000759	0.00251	CcSEcCtD
Toremifene—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000758	0.00251	CcSEcCtD
Toremifene—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000754	0.00249	CcSEcCtD
Toremifene—Fatigue—Vincristine—lymphatic system cancer	0.000753	0.00249	CcSEcCtD
Toremifene—Asthenia—Bleomycin—lymphatic system cancer	0.000752	0.00248	CcSEcCtD
Toremifene—Pain—Vincristine—lymphatic system cancer	0.000747	0.00247	CcSEcCtD
Toremifene—Constipation—Vincristine—lymphatic system cancer	0.000747	0.00247	CcSEcCtD
Toremifene—Pruritus—Bleomycin—lymphatic system cancer	0.000741	0.00245	CcSEcCtD
Toremifene—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000739	0.00244	CcSEcCtD
Toremifene—Fatigue—Mitoxantrone—lymphatic system cancer	0.000733	0.00242	CcSEcCtD
Toremifene—Pain—Mitoxantrone—lymphatic system cancer	0.000727	0.0024	CcSEcCtD
Toremifene—Constipation—Mitoxantrone—lymphatic system cancer	0.000727	0.0024	CcSEcCtD
Toremifene—Vomiting—Bleomycin—lymphatic system cancer	0.000666	0.0022	CcSEcCtD
Toremifene—Rash—Bleomycin—lymphatic system cancer	0.000661	0.00218	CcSEcCtD
Toremifene—Dermatitis—Bleomycin—lymphatic system cancer	0.00066	0.00218	CcSEcCtD
Toremifene—Asthenia—Carmustine—lymphatic system cancer	0.000656	0.00217	CcSEcCtD
Toremifene—Sweating—Methotrexate—lymphatic system cancer	0.000637	0.0021	CcSEcCtD
Toremifene—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000628	0.00208	CcSEcCtD
Toremifene—Asthenia—Vincristine—lymphatic system cancer	0.000627	0.00207	CcSEcCtD
Toremifene—Nausea—Bleomycin—lymphatic system cancer	0.000622	0.00206	CcSEcCtD
Toremifene—Asthenia—Mitoxantrone—lymphatic system cancer	0.00061	0.00202	CcSEcCtD
Toremifene—Dizziness—Carmustine—lymphatic system cancer	0.000605	0.002	CcSEcCtD
Toremifene—Vomiting—Carmustine—lymphatic system cancer	0.000582	0.00192	CcSEcCtD
Toremifene—Dizziness—Vincristine—lymphatic system cancer	0.000577	0.00191	CcSEcCtD
Toremifene—Rash—Carmustine—lymphatic system cancer	0.000577	0.00191	CcSEcCtD
Toremifene—Dermatitis—Carmustine—lymphatic system cancer	0.000576	0.0019	CcSEcCtD
Toremifene—Visual impairment—Methotrexate—lymphatic system cancer	0.000575	0.0019	CcSEcCtD
Toremifene—Headache—Carmustine—lymphatic system cancer	0.000573	0.00189	CcSEcCtD
Toremifene—Eye disorder—Methotrexate—lymphatic system cancer	0.000557	0.00184	CcSEcCtD
Toremifene—Vomiting—Vincristine—lymphatic system cancer	0.000555	0.00183	CcSEcCtD
Toremifene—Rash—Vincristine—lymphatic system cancer	0.000551	0.00182	CcSEcCtD
Toremifene—Dermatitis—Vincristine—lymphatic system cancer	0.00055	0.00182	CcSEcCtD
Toremifene—Headache—Vincristine—lymphatic system cancer	0.000547	0.00181	CcSEcCtD
Toremifene—Nausea—Carmustine—lymphatic system cancer	0.000543	0.0018	CcSEcCtD
Toremifene—Angiopathy—Methotrexate—lymphatic system cancer	0.000541	0.00179	CcSEcCtD
Toremifene—Vomiting—Mitoxantrone—lymphatic system cancer	0.000541	0.00179	CcSEcCtD
Toremifene—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000537	0.00178	CcSEcCtD
Toremifene—Rash—Mitoxantrone—lymphatic system cancer	0.000536	0.00177	CcSEcCtD
Toremifene—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000536	0.00177	CcSEcCtD
Toremifene—Chills—Methotrexate—lymphatic system cancer	0.000535	0.00177	CcSEcCtD
Toremifene—Headache—Mitoxantrone—lymphatic system cancer	0.000533	0.00176	CcSEcCtD
Toremifene—Alopecia—Methotrexate—lymphatic system cancer	0.000527	0.00174	CcSEcCtD
Toremifene—Mental disorder—Methotrexate—lymphatic system cancer	0.000522	0.00173	CcSEcCtD
Toremifene—Malnutrition—Methotrexate—lymphatic system cancer	0.000519	0.00172	CcSEcCtD
Toremifene—Nausea—Vincristine—lymphatic system cancer	0.000519	0.00171	CcSEcCtD
Toremifene—Nausea—Mitoxantrone—lymphatic system cancer	0.000505	0.00167	CcSEcCtD
Toremifene—Back pain—Methotrexate—lymphatic system cancer	0.000502	0.00166	CcSEcCtD
Toremifene—Vision blurred—Methotrexate—lymphatic system cancer	0.000489	0.00162	CcSEcCtD
Toremifene—Vertigo—Methotrexate—lymphatic system cancer	0.000466	0.00154	CcSEcCtD
Toremifene—Leukopenia—Methotrexate—lymphatic system cancer	0.000465	0.00154	CcSEcCtD
Toremifene—Chest pain—Methotrexate—lymphatic system cancer	0.000442	0.00146	CcSEcCtD
Toremifene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000439	0.00145	CcSEcCtD
Toremifene—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000416	0.00137	CcSEcCtD
Toremifene—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000415	0.00137	CcSEcCtD
Toremifene—Skin disorder—Methotrexate—lymphatic system cancer	0.000412	0.00136	CcSEcCtD
Toremifene—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00041	0.00135	CcSEcCtD
Toremifene—Anorexia—Methotrexate—lymphatic system cancer	0.000404	0.00133	CcSEcCtD
Toremifene—Insomnia—Methotrexate—lymphatic system cancer	0.000383	0.00127	CcSEcCtD
Toremifene—Dyspnoea—Methotrexate—lymphatic system cancer	0.000378	0.00125	CcSEcCtD
Toremifene—Decreased appetite—Methotrexate—lymphatic system cancer	0.000368	0.00122	CcSEcCtD
Toremifene—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000366	0.00121	CcSEcCtD
Toremifene—Fatigue—Methotrexate—lymphatic system cancer	0.000365	0.00121	CcSEcCtD
Toremifene—Pain—Methotrexate—lymphatic system cancer	0.000362	0.0012	CcSEcCtD
Toremifene—Asthenia—Methotrexate—lymphatic system cancer	0.000304	0.001	CcSEcCtD
Toremifene—Pruritus—Methotrexate—lymphatic system cancer	0.0003	0.000991	CcSEcCtD
Toremifene—Dizziness—Methotrexate—lymphatic system cancer	0.00028	0.000926	CcSEcCtD
Toremifene—Vomiting—Methotrexate—lymphatic system cancer	0.000269	0.00089	CcSEcCtD
Toremifene—Rash—Methotrexate—lymphatic system cancer	0.000267	0.000883	CcSEcCtD
Toremifene—Dermatitis—Methotrexate—lymphatic system cancer	0.000267	0.000882	CcSEcCtD
Toremifene—Headache—Methotrexate—lymphatic system cancer	0.000265	0.000877	CcSEcCtD
Toremifene—Nausea—Methotrexate—lymphatic system cancer	0.000252	0.000832	CcSEcCtD
